BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S, Janssen HL. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J Hepatol. 2014;60:191-196. [PMID: 23973931 DOI: 10.1016/j.jhep.2013.07.043] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21(1): 233-239 [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
2 Koretz RL, Gurusamy K, Davidson B, Burroughs A. Evidence recommending antiviral therapy in hepatitis C. Journal of Hepatology 2014;60:1101-2. [DOI: 10.1016/j.jhep.2013.12.031] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 van der Meer AJ. Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease? Expert Review of Gastroenterology & Hepatology 2015;9:559-66. [DOI: 10.1586/17474124.2015.1001366] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
4 McDonald SA, Pollock KG, Barclay ST, Goldberg DJ, Bathgate A, Bramley P, Dillon JF, Fraser A, Innes HA, Kennedy N, Morris J, Went A, Hayes PC, Hutchinson SJ. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. J Viral Hepat 2020;27:270-80. [PMID: 31696575 DOI: 10.1111/jvh.13232] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
5 Wedemeyer H, Reimer J, Sandow P, Hueppe D, Lutz T, Gruengreiff K, Goelz J, Christensen S, Pfeiffer-Vornkahl H, Alshuth U, Manns MP. Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study. Liver Int 2017;37:1468-75. [PMID: 28247572 DOI: 10.1111/liv.13399] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
6 Liu CY, Chu JY, Chiang JH, Yen HR, Hsu CH. Utilization and prescription patterns of traditional Chinese medicine for patients with hepatitis C in Taiwan: a population-based study. BMC Complement Altern Med 2016;16:397. [PMID: 27769222 DOI: 10.1186/s12906-016-1379-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
7 van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. Journal of Hepatology 2016;65:S95-S108. [DOI: 10.1016/j.jhep.2016.07.039] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 16.7] [Reference Citation Analysis]
8 Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V, Craxì A, Di Marco V, Cammà C, Calvaruso V, Petta S, Cabbibbo G, Colletti P, Mazzola G, Cascio A, Montalto G, Licata A, Giannitrapani L, Prestileo T, Di Lorenzo F, Sanfilippo A, Ficalora A, Madonia S, Tinè F, Malizia G, Latteri F, Maida M, Cartabellotta F, Vassallo R, Cacciola I, Caccamo G, Maimone S, Saitta C, Squadrito G, Raimondo G, Mondello L, Smedile A, D’andrea S, Bertino G, Ardiri A, Frazzetto E, Rigano G, Montineri A, Larocca L, Cacopardo B, Benanti F, Russello M, Benigno R, Bellia A, Iacobello C, Davì A, Di Rosolini M, Digiacomo A, Fuduli G, Scifo G, Distefano M, Portelli V, Savalli F, Scalici I, Gioia G, Magro A, Alaimo G, Alinovi M, Salvo A, Averna A, Lomonaco F, Guarneri L, Maffeo F, Falzone E, Pulvirenti F. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology 2018;155:411-421.e4. [DOI: 10.1053/j.gastro.2018.04.008] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 38.3] [Reference Citation Analysis]
9 Maan R, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ. Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. J Gastroenterol Hepatol 2015;30:1057-64. [PMID: 25682797 DOI: 10.1111/jgh.12929] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev 2017;30:23-42. [PMID: 27795306 DOI: 10.1128/CMR.00037-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Komatsu T, Virdee S. ICBS and ECBS Chemical Biology Meeting 2015 - Let Them Come to Berlin! ACS Chem Biol 2016;11:1159-66. [PMID: 27198933 DOI: 10.1021/acschembio.6b00268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Nitsche B, Miller SC, Giorgio M, Berry CA, Muir A. Improving Hepatitis C Identification: Technology Alone Is Not the Answer. Health Promot Pract 2018;19:506-12. [PMID: 28893101 DOI: 10.1177/1524839917725501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Schmidt FP, Zimmermann T, Wenz T, Schnorbus B, Ostad MA, Feist C, Grambihler A, Schattenberg JM, Sprinzl MF, Münzel T, Galle PR. Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. International Journal of Cardiology 2018;271:296-300. [DOI: 10.1016/j.ijcard.2018.04.058] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
14 Kwo PY, Shiffman ML, Bernstein DE. The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong. American Journal of Gastroenterology 2018;113:2-4. [DOI: 10.1038/ajg.2017.420] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
15 Maan R, van der Meer AJ. Extending our confidence in sustained virological response. Liver Int 2016;36:794-7. [DOI: 10.1111/liv.13105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 van der Meer AJ. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:364-366. [PMID: 25601636 DOI: 10.1136/gutjnl-2014-308745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Koretz RL, Jakobsen JC, Djurisic S, Poropat G, Hauser G, Bjelakovic M, Bjelakovic G, Gluud C. Who is wrong? Responses to Kwo et al. Am J Gastroenterol 2018;113:779-80. [PMID: 29487409 DOI: 10.1038/s41395-018-0029-4] [Reference Citation Analysis]
18 Chen S, Peng C. Ultrasound-Based Liver Stiffness Surveillance in Patients Treated for Chronic Hepatitis B or C. Applied Sciences 2018;8:626. [DOI: 10.3390/app8040626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
19 Owusu Sekyere S, Port K, Deterding K, Cornberg M, Wedemeyer H. Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients. United European Gastroenterol J 2021;9:486-96. [PMID: 33349201 DOI: 10.1177/2050640620976991] [Reference Citation Analysis]
20 Tsochatzis EA, Crossan C, Longworth L, Gurusamy K, Rodriguez-Peralvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V, Noel-Storr A. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology. 2014;60:832-843. [PMID: 25043847 DOI: 10.1002/hep.27296] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
21 Wranke A, Serrano BC, Heidrich B, Kirschner J, Bremer B, Lehmann P, Hardtke S, Deterding K, Port K, Westphal M, Manns MP, Cornberg M, Wedemeyer H. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology. 2017;65:414-425. [PMID: 27770553 DOI: 10.1002/hep.28876] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
22 Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis. 2015;61:730-740. [PMID: 25987643 DOI: 10.1093/cid/civ396] [Cited by in Crossref: 184] [Cited by in F6Publishing: 167] [Article Influence: 26.3] [Reference Citation Analysis]
23 Janczewska E, Flisiak R, Zarebska-Michaluk D, Kozielewicz D, Berak H, Dobracka B, Librant-Suska M, Lojewski W, Jurczyk K, Musialik J, Postawa-Klosińska B, Wroblewski J, Augustyniak K, Dudziak M, Olszok I, Ruszala A, Pisula A, Lapinski T, Kryczka W, Horban A, Dobracki W. Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study. Medicine (Baltimore) 2015;94:e1411. [PMID: 26402801 DOI: 10.1097/MD.0000000000001411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
24 Fujii H, Kimura H, Hasebe C, Akahane T, Satou T, Kusakabe A, Kojima Y, Kondo M, Marusawa H, Kobashi H, Tsuji K, Ogawa C, Uchida Y, Joko K, Mitsuda A, Kurosaki M, Izumi N. Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. JGH Open. [DOI: 10.1002/jgh3.12749] [Reference Citation Analysis]
25 Paolucci S, Piralla A, Novazzi F, Fratini A, Maserati R, Gulminetti R, Novati S, Barbarini G, Sacchi P, Silvestri A, Baldanti F. Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs. Viruses 2020;12:E255. [PMID: 32106574 DOI: 10.3390/v12030255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Álvaro-Meca A, Jiménez-Sousa MA, Boyer A, Medrano J, Reulen H, Kneib T, Resino S. Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit. BMC Infect Dis 2016;16:122. [PMID: 26979964 DOI: 10.1186/s12879-016-1448-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Wranke A, Wedemeyer H. Antiviral therapy of hepatitis delta virus infection - progress and challenges towards cure. Curr Opin Virol. 2016;20:112-118. [PMID: 27792905 DOI: 10.1016/j.coviro.2016.10.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
28 Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology. 2014;60:1187-1195. [PMID: 25065814 DOI: 10.1002/hep.27340] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]